Barclays PLC Grows Stock Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Barclays PLC lifted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 69.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 445,795 shares of the company's stock after buying an additional 182,138 shares during the quarter. Barclays PLC owned 0.22% of Cellebrite DI worth $9,821,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. R Squared Ltd acquired a new position in shares of Cellebrite DI in the 4th quarter worth approximately $100,000. Polen Capital Management LLC purchased a new stake in Cellebrite DI during the fourth quarter valued at about $222,000. Victory Capital Management Inc. acquired a new stake in shares of Cellebrite DI during the fourth quarter valued at approximately $234,000. HighTower Advisors LLC purchased a new stake in shares of Cellebrite DI in the fourth quarter valued at $274,000. Finally, Pictet Asset Management Holding SA purchased a new position in Cellebrite DI during the 4th quarter valued at about $283,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $18.39 on Wednesday. The stock has a 50-day simple moving average of $18.79 and a 200 day simple moving average of $20.10. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30. The stock has a market capitalization of $4.40 billion, a PE ratio of -13.23, a P/E/G ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, equities research analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on CLBT shares. Lake Street Capital lifted their price objective on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Needham & Company LLC reissued a "buy" rating and set a $28.00 price objective on shares of Cellebrite DI in a report on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. boosted their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.